This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Leukaemia
  • /
  • Ibrutinib and its use in the treatment of chronic ...
Journal

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

Read time: 1 mins
Published:15th Dec 2017
Author: Frustaci AM, Tedeschi A, Deodato M, Mazzucchelli M, Cairoli R, Montillo M.
Source: Future Oncology
Availability: Pay for access, or by subscription
Ref.:Future Oncol. 2017.
DOI:10.2217/fon-2017-0466

Ibrutinib represents a revolution in chronic lymphocytic leukemia treatment scenario providing results never seen before and offering an effective therapy even in high-risk patients with really poor outcome after chemoimmunotherapy. Thanks to longer updates, on one hand, ibrutinib has confirmed its efficacy continuing to show clinical benefits over time; on the other hand, resistance mechanisms are slowly emerging. Moreover, clinicians should be aware of ibrutinib-related side effects, paying attention to screen patients that could benefit more from the drug and try to prevent adverse events. While ibrutinib approval indication is expanding, high treatment costs will shortly require a selection of those who can really draw advantage from Bruton's tyrosine kinase inhibition and those who could continue to be treated with chemoimmunotherapy.

 

Read abstract on library site

Access full article